Want to see EXOZ full AI Analyst Report?
Top Page
eXoZymes
(NASDAQ:EXOZ)
Select Model
Select Model
Rating:41Neutral
Price Target:
$4.00
▼(-44.21% Downside)
Action:Reiterated
Date:10/16/26
The score is primarily held down by weak financial performance (no revenue, widening losses, and ongoing cash burn) and a strongly bearish technical setup with the stock trading well below key moving averages. Valuation signals provide little support due to negative earnings and no indicated dividend.
Positive Factors
Reduced Debt
Lower debt reduces near-term balance-sheet pressure and leaves the company less exposed to interest and refinancing burdens than in 2025. The approximately 0.20 debt-to-equity ratio indicates leverage is moderate, providing some financial flexibility while operations remain loss-making.
Negative Factors
No Revenue and Widening Losses
A prolonged absence of revenue means the company has not yet demonstrated commercial traction or a functioning revenue engine. Expanding losses further increase the distance to self-sustaining operations, making future funding and successful commercialization central to the investment case.
Read all positive and negative factors
Positive Factors
Negative Factors
Reduced Debt
Lower debt reduces near-term balance-sheet pressure and leaves the company less exposed to interest and refinancing burdens than in 2025. The approximately 0.20 debt-to-equity ratio indicates leverage is moderate, providing some financial flexibility while operations remain loss-making.
Read all positive factors
eXoZymes (EXOZ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$39.21M
Dividend YieldN/A
Average Volume (3M)11.18K
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue GrowthN/A
EPS Growth-21.64%
CountryUS
Employees32
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.20
Shares Outstanding9,281,359
10 Day Avg. Volume17,510
30 Day Avg. Volume11,177
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)26.89
Price to Sales (P/S)0.00
P/FCF Ratio-13.69
Enterprise Value/Market Cap1.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit997.47
Enterprise Value/Ebitda-6.51
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
eXoZymes Business Overview & Revenue Model
Company Description
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, ...
How the Company Makes Money
null...
eXoZymes Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 68.61K | 0.00 | -267.38K | 0.00 | -147.75K | -59.41K |
| EBITDA | -10.51M | -8.98M | -5.59M | -1.80M | -1.18M | -1.15M |
| Net Income | -10.19M | -9.16M | -5.86M | -2.04M | -1.40M | -1.21M |
Balance Sheet | ||||||
| Total Assets | 7.98M | 5.97M | 13.03M | 3.56M | 2.69M | 2.35M |
| Cash, Cash Equivalents and Short-Term Investments | 5.65M | 3.04M | 9.72M | 66.53K | 558.57K | 547.81K |
| Total Debt | 1.09M | 1.24M | 1.39M | 1.61M | 608.77K | 720.63K |
| Total Liabilities | 4.33M | 2.57M | 2.61M | 3.94M | 1.31M | 1.15M |
| Stockholders Equity | 3.65M | 3.40M | 10.42M | -384.32K | 1.37M | 1.20M |
Cash Flow | ||||||
| Free Cash Flow | -7.14M | -6.67M | -8.90M | -1.47M | -1.44M | -2.01M |
| Operating Cash Flow | -7.00M | -6.50M | -8.51M | -1.18M | -1.26M | -1.59M |
| Investing Cash Flow | -145.90K | -150.22K | -359.22K | -311.17K | -87.21K | -312.25K |
| Financing Cash Flow | 5.81M | -27.71K | 18.52M | 1.00M | 1.36M | 2.31M |
eXoZymes Technical Analysis
Negative
7.17
Price Trends
5.78
Negative
6.12
Negative
7.83
Negative
Market Momentum
-0.55
Positive
37.38
Neutral
31.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EXOZ, the sentiment is Negative. The current price of 7.17 is above the 20-day moving average (MA) of 4.63, above the 50-day MA of 5.78, and below the 200-day MA of 7.83, indicating a bearish trend. The MACD of -0.55 indicates Positive momentum. The RSI at 37.38 is Neutral, neither overbought nor oversold. The STOCH value of 31.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EXOZ.
eXoZymes Risk Analysis
eXoZymes disclosed 47 risk factors in its most recent earnings report. eXoZymes reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
eXoZymes Peers Comparison
UnderperformOutperform
Sector (55)
EXOZ
eXoZymes
4.23
-8.43
-66.60%
BDRX
Biodexa Pharmaceuticals
4.14
-240.26
-98.31%
ADTX
Aditxt
0.04
-1,659.70
-100.00%
NCEL
NewcelX
2.70
-4.92
-64.57%
VRAX
Virax Biolabs Group Ltd. Class A
1.20
-13.63
-91.91%
eXoZymes Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
eXoZymes Highlights Investor Presentation for Capital Markets Outreach
Positive
Oct 9, 2026
On October 6, 2026, eXoZymes Inc. prepared an investor presentation intended for distribution to investment bankers, offering participants, and existing and prospective investors. The document, filed as an exhibit, is designed to support the compa...
Shareholder Meetings
eXoZymes Sets Date for 2026 Shareholders Meeting
Neutral
Sep 18, 2026
eXoZymes announced that it scheduled its 2026 annual meeting of shareholders for November 13, 2026, setting a formal timeline for its upcoming governance and voting activities. The company established September 15, 2026 as the record date to deter...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.